0000000000524567

AUTHOR

Giovanni Antonini

0000-0002-7519-7739

showing 7 related works from this author

"I Know that You Know that I Know": Neural Substrates Associated with Social Cognition Deficits in DM1 Patients.

2016

Myotonic dystrophy type-1 (DM1) is a genetic multi-systemic disorder involving several organs including the brain. Despite the heterogeneity of this condition, some patients with non-congenital DM1 can present with minimal cognitive impairment on formal testing but with severe difficulties in daily-living activities including social interactions. One explanation for this paradoxical mismatch can be found in patients' dysfunctional social cognition, which can be assessed in the framework of the Theory of Mind (ToM). We hypothesize here that specific disease driven abnormalities in DM1 brains may result in ToM impairments. We recruited 20 DM1 patients who underwent the "Reading the Mind in th…

MaleSocial CognitionMagnetic Resonance SpectroscopyTheory of MindAdult; Brain; Cognition; Female; Humans; Magnetic Resonance Spectroscopy; Male; Middle Aged; Myotonic Dystrophy; Neuropsychological Tests; Social Behavior; Theory of MindSocial Scienceslcsh:MedicineDiseaseNeuropsychological TestsDiagnostic RadiologyCognition0302 clinical medicineFunctional Magnetic Resonance ImagingTheory of mindMedicine and Health SciencesPsychologyMyotonic Dystrophylcsh:ScienceCognitive ImpairmentBrain MappingMultidisciplinarymedicine.diagnostic_testCognitive NeurologyRadiology and Imagingagricultural and biological sciences (all); biochemistry genetics and molecular biology (all); medicine (all)05 social sciencesRBrainCognitionMiddle AgedMagnetic Resonance ImagingNeurologyRC0346Genetic DiseasesPhysical SciencesFemaleSettore MED/26 - NeurologiaPsychologyResearch ArticleClinical psychologyAdultmusculoskeletal diseasesComputer and Information Sciencesmedicine.medical_specialtycongenital hereditary and neonatal diseases and abnormalitiesSocial PsychologyImaging TechniquesCognitive NeuroscienceNeuroimagingDysfunctional familyResearch and Analysis MethodsMyotonic dystrophy050105 experimental psychology03 medical and health sciencesDiagnostic MedicineSocial cognitionTheory of mind cerebral lesionGeneticsmedicineHumans0501 psychology and cognitive sciencesSocial BehaviorPsychiatryClinical GeneticsSettore M-PSI/02 - Psicobiologia E Psicologia Fisiologicalcsh:RCognitive PsychologyBiology and Life SciencesHuman Geneticsmedicine.diseaseComprehensionGraph TheoryRC0321Cognitive Sciencelcsh:QFunctional magnetic resonance imagingMathematics030217 neurology & neurosurgeryNeurosciencePLoS ONE
researchProduct

Atypical CIDP: diagnostic criteria, progression and treatment response. Data from the Italian CIDP Database

2019

ObjectivesA few variants of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) have been described, but their frequency and evolution to typical CIDP remain unclear. To determine the frequency and characteristics of the CIDP variants, their possible evolution to typical CIDP, and treatment response.MethodsWe applied a set of diagnostic criteria to 460 patients included in a database of Italian patients with CIDP. Clinical characteristics and treatment response were reviewed for each patient. The Kaplan-Meier curve was used to estimate the progression rate from atypical to typical CIDP.ResultsAt the time of inclusion, 376 (82%) patients had a diagnosis of typical CIDP while 84 …

AdultMaleTreatment responselewis-sumner syndromeAdolescentDatabases FactualDisease durationchronic inflammatory demyelinating polyradiculoneuropathy; CIDP; diagnostic criteria; distal acquired demyelinating symmetric neuropathy; lewis-sumner syndrome; Surgery; Neurology (clinical); Psychiatry and Mental HealthKaplan-Meier EstimateCIDPcomputer.software_genreDisease courseYoung Adultlewis–sumner syndrome03 medical and health sciences0302 clinical medicineHumansMedicineIn patientChildAgedRetrospective StudiesAged 80 and overchronic inflammatory demyelinating polyradiculoneuropathyRetrospective reviewdistal acquired demyelinating symmetric neuropathyDatabasebusiness.industryPolyradiculoneuropathyMiddle Agedchronic inflammatory demyelinating polyradiculoneuropathy; CIDP; diagnostic criteria; distal acquired demyelinating symmetric neuropathy; lewis-sumner syndromemedicine.diseasePsychiatry and Mental healthchronic inflammatory demyelinating polyradiculoneuropathy; CIDP; diagnostic criteria; distal acquired demyelinating symmetric neuropathy; lewis-sumner syndrome; surgery; neurology ; psychiatry and mental healthItalyPolyradiculoneuropathy Chronic Inflammatory Demyelinatingdiagnostic criteriaDisease ProgressionFemaleSettore MED/26 - NeurologiaSurgeryProgression rateNeurology (clinical)CIDP; chronic inflammatory demyelinating polyradiculoneuropathy; diagnostic criteria; distal acquired demyelinating symmetric neuropathy; lewis–sumner syndromebusinesscomputer030217 neurology & neurosurgeryJournal of Neurology, Neurosurgery & Psychiatry
researchProduct

Protein misfolding, amyotrophic lateral sclerosis and guanabenz: Protocol for a phase II RCT with futility design (ProMISe trial)

2017

IntroductionRecent studies suggest that endoplasmic reticulum stress may play a critical role in the pathogenesis of amyotrophic lateral sclerosis (ALS) through an altered regulation of the proteostasis, the cellular pathway-balancing protein synthesis and degradation. A key mechanism is thought to be the dephosphorylation of eIF2α, a factor involved in the initiation of protein translation. Guanabenz is an alpha-2-adrenergic receptor agonist safely used in past to treat mild hypertension and is now an orphan drug. A pharmacological action recently discovered is its ability to modulate the synthesis of proteins by the activation of translational factors preventing misfolded protein accumula…

0301 basic medicineOncologyPathologyamyotrophic lateral sclerosisamyotrophic lateral sclerosis; motor neurone disease; neuromuscular disease; randomized clinical trial guanabenz; unfolded protein response; adrenergic alpha-2 receptor agonist s; age of onset; amyotrophic lateral sclerosis; disease progression; double-blind method; endoplasmic reticulum stress; guanabenz; humans; italy; medical futility; neuroprotective agents; proteostasis deficienciesamyotrophic lateral sclerosis; motor neurone disease; neuromuscular disease; randomized clinical trial guanabenz; unfolded protein response; Medicine (all)randomized clinical trial guanabenzHelsinki declaration0302 clinical medicineProtocolAdrenergic alpha-2 Receptor Agonists1506Amyotrophic lateral sclerosisAge of OnsetGuanabenzMedicine (all)amyotrophic lateral sclerosis; motor neurone disease; neuromuscular disease; randomized clinical trial guanabenz; unfolded protein responseNeurodegenerationamyotrophic lateral sclerosis; motor neurone disease; neuromuscular disease; randomized clinical trial guanabenz; unfolded protein response;amyotrophic lateral sclerosis; guanabenz; motor neurone disease; neuromuscular disease; randomized clinical trial; unfolded protein response; Adrenergic alpha-2 Receptor Agonists; Age of Onset; Amyotrophic Lateral Sclerosis; Disease Progression; Double-Blind Method; Endoplasmic Reticulum Stress; Guanabenz; Humans; Italy; Medical Futility; Neuroprotective Agents; Proteostasis DeficienciesGeneral Medicineunfolded protein responseEndoplasmic Reticulum StressRiluzoleNeuroprotective AgentsNeurologyTolerabilityItalyDisease Progression1713GuanabenzMedical Futilitymedicine.drugmedicine.medical_specialtyamyotrophic lateral sclerosis; motor neurone disease; neuromuscular disease; randomized clinical trial guanabenz; unfolded protein response; Adrenergic alpha-2 Receptor Agonists; Age of Onset; Amyotrophic Lateral Sclerosis; Disease Progression; Double-Blind Method; Endoplasmic Reticulum Stress; Guanabenz; Humans; Italy; Medical Futility; Neuroprotective Agents; Proteostasis Deficiencies; Medicine (all)Neuroprotection03 medical and health sciencesmotor neurone diseaseDouble-Blind MethodInternal medicinemedicineHumansProteostasis Deficienciesbusiness.industryAmbientaleneuromuscular diseaserandomized clinical trialmedicine.diseaseClinical trial030104 developmental biologybusiness030217 neurology & neurosurgery
researchProduct

Sensitivity and specificity of a commercial ELISA test for anti-MAG antibodies in patients with neuropathy

2020

For the diagnosis of anti-MAG polyneuropathy the commercial ELISA manufacturer currently recommends a cut-off of 1000 Bühlmann Titer Units (BTU). We analyzed sera from 80 anti-MAG neuropathy patients and 383 controls (with other neuropathies or healthy controls) to assess the ELISA sensitivity and specificity at different thresholds. A better combination of sensitivity/specificity was found at a threshold >1500 BTU than at >1000 BTU. The best value of specificity was obtained at threshold >7000 BTU. There was a diagnostic grey area between 1500 and 7000 BTU in which the clinical phenotypes as well as electrophysiological studies need to be carefully assessed particularly to differe…

0301 basic medicinemedicine.medical_specialtyanti-MAG polyneuropathy; chronic inflammatory demyelinating polyradiculoneuropathy; ELISA; sensitivity; specificity; autoantibodies; case-control studies; enzyme-linked immunosorbent assay; humans; myelin-associated glycoprotein; polyneuropathies; retrospective studiesImmunologyAnti-MAG polyneuropathyEnzyme-Linked Immunosorbent AssaySettore MED/26GastroenterologyPolyneuropathies03 medical and health sciencesSensitivity0302 clinical medicineInternal medicinemedicineHumansImmunology and AllergyIn patientAutoantibodiesRetrospective Studieschronic inflammatory demyelinating polyradiculoneuropathyAnti-MAG polyneuropathy chronic inflammatory demyelinating polyradiculoneuropathybiologybusiness.industryAnti magAnti-MAG polyneuropathy chronic inflammatory demyelinating polyradiculoneuropathy; ELISA; Sensitivity; Specificitymedicine.diseaseAutoantibodieMyelin-Associated GlycoproteinTiter030104 developmental biologyPolyneuropathienervous systemNeurologyCase-Control StudiesElisa testSpecificitybiology.proteinELISANeurology (clinical)AntibodyCase-Control StudiebusinessSensitivity (electronics)Polyneuropathy030217 neurology & neurosurgeryHumanJournal of Neuroimmunology
researchProduct

Risk factors for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): antecedent events, lifestyle and dietary habits. Data from the Ita…

2020

Background and purpose: The role of lifestyle and dietary habits and antecedent events has not been clearly identified in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Methods: Information was collected about modifiable environmental factors and antecedent infections and vaccinations in patients with CIDP included in an Italian CIDP Database. Only patients who reported not having changed their diet or the lifestyle habits investigated in the study after the appearance of CIDP were included. The partners of patients with CIDP were chosen as controls. Gender-matched analysis was performed with randomly selected controls with a 1:1 ratio of patients and controls. Results: D…

AdultMalemedicine.medical_specialtylifestyleDatabases FactualDiseasecomputer.software_genreSettore MED/26chronic inflammatory demyelinating neuropathy; chronic inflammatory demyelinating polyradiculoneuropathy; diet; epidemiology; infections; lifestyle; vaccination03 medical and health sciences0302 clinical medicineRisk FactorsEpidemiologymedicineHumans030212 general & internal medicineinfectionsRisk factorChildLife Stylechronic inflammatory demyelinating polyradiculoneuropathyDatabasebusiness.industryAntecedent variablechronic inflammatory demyelinating neuropathyPolyradiculoneuropathyFeeding BehaviorMiddle Agedmedicine.diseasevaccinationinfectionSettore MED/26 - NEUROLOGIAAntecedent (behavioral psychology)ItalyPolyradiculoneuropathy Chronic Inflammatory DemyelinatingNeurologyFemaleepidemiologyNeurology (clinical)ComplicationbusinessLifestyle habitsdietcomputer030217 neurology & neurosurgery
researchProduct

Dataset related to article "Chronic inflammatory demyelinating polyradiculoneuropathy: can a diagnosis be made in patients not fulfilling electrodiag…

2021

This record contains data related to article “Chronic inflammatory demyelinating polyradiculoneuropathy: can a diagnosis be made in patients not fulfilling electrodiagnostic criteria?" Abstract Background and purpose: The aim was to identify the clinical and diagnostic investigations that may help to support a diagnosis of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) in patients not fulfilling the European Federation of Neurological Societies and Peripheral Nerve Society (EFNS/PNS) electrodiagnostic criteria. Methods: The data from patients with a clinical diagnosis of CIDP included in a national database were retrospectively reviewed. Results: In all, 535 p…

chronic inflammatory demyelinating polyradiculoneuropathydiagnostic criteriaelectrophysiology
researchProduct

Dataset relative to article "Sensitivity and specificity of a commercial ELISA test for anti-MAG antibodies in patients with neuropathy"

2021

This record contains data related to article “Sensitivity and specificity of a commercial ELISA test for anti-MAG antibodies in patients with neuropathy". Abstract For the diagnosis of anti-MAG polyneuropathy the commercial ELISA manufacturer currently recommends a cut-off of 1000 Bühlmann Titer Units (BTU). We analyzed sera from 80 anti-MAG neuropathy patients and 383 controls (with other neuropathies or healthy controls) to assess the ELISA sensitivity and specificity at different thresholds. A better combination of sensitivity/specificity was found at a threshold >1500 BTU than at >1000 BTU. The best value of specificity was obtained at threshold >7000 BTU. There…

chronic inflammatory demyelinating polyradiculoneuropathySensitivitynervous systemAnti-MAG polyneuropathyELISASpecificity.
researchProduct